Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2022 | editorial

COVID-19 crisis and cancer

verfasst von: Assoc.-Prof. Dr. Rupert Bartsch, Prof. Dr. Wolfgang Hilbe

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Excerpt

It sometimes feels that SARS-CoV‑2 has been around forever, and yet the pandemics started only two years ago. The speed of vaccine development was fantastic, and vaccination programs for a high-risk population started in earnest in early 2021. In November 2020, just before patients, relatives and the medical staff had the chance to be vaccinated and be protected from severe courses of a COVID-19 infection, we were frightened to experience clusters of infections in the vulnerable group of cancer patients or to be infected ourselves. Nearly all oncological departments experienced both clusters of infections in patients and in staff members, leading to a reduced number of nurses and physicians being on duty. …
Vorheriger Artikel New targeted therapies/small molecules in oncology and hematology
Nächster Artikel COVID-19: New disease mechanism is simultaneously a therapeutic target
Literatur
1.
2.
3.
Metadaten
Titel
COVID-19 crisis and cancer
verfasst von
Assoc.-Prof. Dr. Rupert Bartsch
Prof. Dr. Wolfgang Hilbe
Publikationsdatum
01.06.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00812-x

Weitere Artikel der Ausgabe 2/2022

Tracking mutation and drug-driven alterations of oncokinase conformations

  • Open Access
  • short review

Hemophagocytic lymphohistocytosis in a COVID-19 patient in the acute phase: case report

  • case report

Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022

  • Open Access
  • short review

ESMO 2021—my top three abstracts in breast cancer

  • Open Access
  • short review

New targeted therapies in kidney cancer

  • short review

COVID-19: New disease mechanism is simultaneously a therapeutic target

  • editorial